Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01718093 · ClinicalTrials.gov registry record · Phase 4
A Pilot Study to Assess the Glucose Lowering Effect of Metformin and Sitagliptin in Adolescents With Type 1 Diabetes
A Phase 4 study of Type 1 Diabetes, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 4
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT01718093: Completed Phase 4 study of Type 1 Diabetes, sponsored by Baylor College of Medicine.
NCT01718093 is a Phase 4 study of Type 1 Diabetes that has completed, run by Baylor College of Medicine. The registered enrollment target is 21 participants, below the 767-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01718093, a Phase 4 study of Type 1 Diabetes, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see if the use of metformin and sitagliptin used in conjunction with insulin can improve the blood sugars of teenagers with Type 1 diabetes.
Primary Outcome
Glucose concentrations and AUC glucose calculation
Conditions Studied
Interventions
- DRUG Metformin
- DRUG Sitagliptin
- DRUG Sitagliptin + Metformin
Study Locations (1)
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2012-10 |
| Est. Completion | 2015-12 |
| Phase | Phase 4 |
What the finished NCT01718093 record still lists
NCT01718093 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 767-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 3 interventions - of which Metformin is the first listed.
NCT01718093 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT01718093 about?
NCT01718093 is a clinical study titled "A Pilot Study to Assess the Glucose Lowering Effect of Metformin and Sitagliptin in Adolescents With Type 1 Diabetes". The purpose of this study is to see if the use of metformin and sitagliptin used in conjunction with insulin can improve the blood sugars of teenagers with Type 1 diabetes.
What is the current status of trial NCT01718093?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 21 participants. The study started on 2012-10. Estimated completion is 2015-12.
What conditions does trial NCT01718093 study?
This clinical trial studies the following conditions: Type 1 Diabetes.
What interventions are being tested in trial NCT01718093?
The interventions under investigation include: Metformin (DRUG), Sitagliptin (DRUG), Sitagliptin + Metformin (DRUG).
Who is sponsoring clinical trial NCT01718093?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01718093 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01718093's enrollment target sits among peer trials
21 150th of 198 higher than 48 of 198 other Type 1 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 1 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Extended Bolus for Meals in a Closed-loop System
RECRUITING · Phase 4
-
Cholesterol Lowering and Residual Risk in Diabetes, Type 1
RECRUITING · Phase 4
-
Diabetes in African Youth
RECRUITING · Phase 4
-
Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose
COMPLETED · Phase 4
-
Lunch Time Insulin Injection by School Nurse for Poorly Controlled Diabetes
COMPLETED · Phase 4
-
Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia